Condition: Metastatic Invasive Lobular Carcinoma (mILC) · Sponsor: Julia Foldi
The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.
This description comes directly from the study's public registry record.
Lucia Borasso, BA · 4126413304 · borrlm@upmc.edu
Kelsey Mitch, RN · 4126412357 · adamikka2@upmc.edu
Always discuss trial participation with your own doctor first.
| Magee Women's Hospital of UPMC | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06666439